EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

The Clinical Effectiveness of Fidaxomicin Compared to Vancomycin in the Treatment of Clostridioides difficile Infection, A Single-Center Real-World Experience

Majd Alsoubani iD, Jennifer K Chow, Angie Mae Rodday, Laura A McDermott, Seth T Walk, David M Kent, David R Snydman

The Journal of Infectious Diseases · 2024

DOI: 10.1093/infdis/jiae274 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Majd Alsoubani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Geographic Medicine and Infectious Diseases, Department of Medicine, Tufts Medical Center, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Fidaxomicin, Vancomycin, Clostridium Infections, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Tupper Family Foundation, NIH HHS, Tufts Medical Center;.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The use of fidaxomicin is recommended as first-line therapy for all patients with Clostridioides difficile infection (CDI). However, real-world studies have shown conflicting evidence of superiority.

Methods

We conducted a retrospective single-center study of patients diagnosed with CDI between 2011 and 2021. A primary composite outcome of clinical failure, 30-day relapse, or CDI-related death was used. A multivariable cause-specific Cox proportional hazards model was used to evaluate fidaxomicin compared to vancomycin in preventing the composite outcome. A separate model was fit on a subset of patients with C. difficile ribotypes adjusting for ribotype.

Results

There were 598 patients included, of whom 84 received fidaxomicin. The primary outcome occurred in 8 (9.5%) in the fidaxomicin group compared to 111 (21.6%) in the vancomycin group. The adjusted multivariable model showed fidaxomicin was associated with 63% reduction in the risk of the composite outcome compared to vancomycin (hazard ratio [HR] = 0.37; 95% confidence interval [CI], .17–.80). In the 337 patients with ribotype data after adjusting for ribotype 027, the results showing superiority of fidaxomicin were maintained (HR = 0.19; 95% CI, .05–.77).

Conclusions

In the treatment of CDI, we showed that real-world use of fidaxomicin is associated with lower risk of a composite end point of treatment failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FidaxomicinVancomycinClostridium InfectionsAnti-Bacterial AgentsClostridioides difficileHumansFemaleMaleRetrospective StudiesAgedMiddle AgedTreatment OutcomeRecurrenceAged, 80 and overProportional Hazards ModelsRibotyping

Stichwörter der Autor:innen

Clostridioides difficileCDIfidaxomicinoral vancomycinribotype 027

Substanzen

FidaxomicinVancomycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Division of Geographic Medicine and Infectious Diseases, Department of Medicine, Tufts Medical Center, Boston, Massachusetts, USA.
  • The Stuart B. Levy Center for the Integrated Management of Antimicrobial Resistance, Tufts University School of Medicine, Boston, Massachusetts, USA.
  • Tufts Clinical and Translational Science Institute, Tufts Medical Center, Boston, Massachusetts, USA.
  • Department of Microbiology and Immunology, Montana State University, Bozeman, Montana, USA.
  • Predictive Analytics and Comparative Effectiveness Center, Tufts Medical Center/Tufts University School of Medicine, Boston, Massachusetts, USA.

ORCID-Profile: Majd Alsoubani

Förderung

  • Tupper Family Foundation
  • NIH HHS
  • Tufts Medical Center;
  • Merck & Co
  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences
  • National Institutes of Health

Zitieren

APA

Alsoubani, M., Chow, J. K., Rodday, A. M., McDermott, L. A., Walk, S. T., Kent, D. M., & Snydman, D. R. (2024). The Clinical Effectiveness of Fidaxomicin Compared to Vancomycin in the Treatment of Clostridioides difficile Infection, A Single-Center Real-World Experience. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae274

Vancouver

Alsoubani M, Chow JK, Rodday AM, McDermott LA, Walk ST, Kent DM, et al. The Clinical Effectiveness of Fidaxomicin Compared to Vancomycin in the Treatment of Clostridioides difficile Infection, A Single-Center Real-World Experience. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae274

BibTeX
@article{Alsoubani2024,
  author = {Alsoubani, Majd and Chow, Jennifer K and Rodday, Angie Mae and McDermott, Laura A and Walk, Seth T and Kent, David M and Snydman, David R},
  title = {The Clinical Effectiveness of Fidaxomicin Compared to Vancomycin in the Treatment of Clostridioides difficile Infection, A Single-Center Real-World Experience},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  doi = {10.1093/infdis/jiae274}
}
Kostenlos starten →